Health

  • |

    Public Cancer Research, Private Cancer Profits: The Taxpayer Paid Twice

    ByPhil McCracken

    I followed the Taxol invoice, and the handwriting gets suspiciously fancy near the bottom. Publicly supported NIH research helped carry the scientific risk behind paclitaxel, while Bristol Myers Squibb became the name attached to the commercial blockbuster. The exact accounting deserves careful checking, but the central complaint is hard to miss: shared research can become private revenue before the public gets a meaningful return.

    That is the pharmaceutical business model in a lab coat. Taxpayers help finance the runway, private interests get the applause, and patients are handed the receipt for progress they helped make possible. Nobody objects to a company earning money by bringing a treatment to patients; the question is why public investment so often exits through the front door while public accountability is left waiting in the lobby. Follow the invoice long enough and “research for all” can end with profits for the private and a second bill for the sick.

  • |

    The Drug Pricing Rule Has a Lobbyist in the Back Seat

    ByPhil McCracken

    I look at Washington’s healthcare paperwork the way a diner waitress looks at a fake coupon: polite, tired, and already hunting for the fine print. CMS is considering a proposed Medicare rule that could treat certain fixed-combination drugs as the same qualifying single-source drug as an originator medicine for price negotiation. Patients may see one prescription. The policy question is whether Washington sees one product—or several convenient identities parked under the same hood.

    CMS issued the proposal June 12, set an August 17 comment deadline, and is expected to finalize it in fall 2026. That makes this less a chemistry quiz than a money-trail dispute. If a combination product remains legally separate from the medicine it combines, more revenue could remain outside the negotiation process. That is not proof anyone designed the product as an escape hatch. It is the practical question sitting on the counter while everyone argues about labels.

    Inside Health Policy reported that biologics manufacturers objected to CMS’s approach, arguing that separate FDA categories raise legal-authority and innovation concerns. Those are serious arguments, and agencies should not smuggle major policy changes through a filing cabinet labeled “technical clarification.” But the industry’s preferred separation also has a financial consequence: separate categories can mean separate treatment when Medicare decides what qualifies for negotiation.

    This is where the fine print starts wearing donor perfume. The public argument is about innovation, regulatory boundaries, and whether CMS has gone too far. The money question is simpler: who benefits if the category stays split? Manufacturers may preserve separate revenue streams from negotiated pricing, while patients and taxpayers are left to admire the elegance of the classification system from the payment window.

    At the pharmacy drive-through, nobody orders “one originator medicine with a regulatory garnish.” They get a prescription. In Washington, however, one prescription can be asked to produce two billing identities, two receipts, and two opportunities to keep the negotiated-price window closed. The rule is still proposed, the dispute is still active, and the invoice has not finished crawling out from under the lobbyist’s coat. But the public should know what this technical fight can decide: whether a medicine’s category serves patients—or protects the revenue attached to it.

    Sources

  • |

    When Efficiency Locks the Front Door

    ByHarlan Quill

    I ran the arithmetic on the Biden-Harris plan to expand home-based care versus the Trump policy freeze described around CMS, and the numbers have a familiar county-office quality: fewer new providers may look tidy on paper, but a locked door is not an appointment. Supporting family caregivers, improving care jobs, and helping seniors remain independent all require actual capacity—not merely a promise that capacity would be nice.

    Fraud prevention matters. So does not confusing “fewer entrants” with “better access.” If legitimate home-health agencies and hospice providers cannot get through the front door, seniors wait, families absorb another unpaid shift, and care workers are asked to perform fiscal miracles before lunch. The spreadsheet may show fewer bad actors. It also shows a locked door, and the person outside still needs a caregiver.

  • |

    The Prior Authorization Desk Needs Prior Authorization

    ByHugh Jass

    I have reviewed the federal audit, and the document coughed before I did: Health Share of Oregon’s prior-authorization denial process was not consistently meeting the rules that make those denials lawful, timely, understandable, and properly reviewed. The HHS Office of Inspector General examined 100 Medicaid denials and found that 21 failed to comply with at least one federal or state requirement. This is the bureaucratic equivalent of a courthouse discovering its front door requires a permit.

    The failures were not confined to one ceremonial checkbox. OIG identified problems involving the expertise used to make decisions, the content of denial notices, the timing of those notices, language access, and communication with providers. In other words, the system responsible for explaining why care was denied sometimes struggled with the basic administrative duties required to explain a denial. Exhibit A had a pulse, and it was asking where Exhibit B went.

    OIG estimated that the findings could represent 5,677 noncompliant denials during calendar year 2023. That estimate does not mean every denial was improper, and the audit does not decide whether particular treatments were medically necessary. It identifies something more elemental and, in its own way, more haunting: the gatekeeper enforcing authorization rules did not consistently satisfy the rules governing its own decisions.

    The agency issued four recommendations to Health Share of Oregon. Those recommendations are the usual institutional medicine: review procedures, improve oversight, train the machinery, and make sure the paperwork behaves before it is allowed near another human life. Necessary, presumably. But somewhere in the records room, a form is being prepared for the denial department itself.

    Therefore, as a matter of administrative justice, the prior-authorization desk should submit its own application for prior authorization. It should demonstrate expertise, deliver a timely and understandable notice, provide language access, and consult the people who actually know what is happening. Until then, patients and providers are being asked to trust a stack of paperwork that the stack could not consistently complete correctly. The filing blinked first.

  • |

    The Public Helped Prove Remdesivir—Then Got the Invoice

    ByPhil McCracken

    I follow the invoice, and Remdesivir leads straight to the strangest line item in pandemic economics: public support helping carry the research risk while Gilead’s approximately $3,120 list-price headline arrives like the taxpayer has never met the taxpayer. That figure was not necessarily every patient’s final bill, and public funding did not pay for every step of the work. But the fairness problem remains plain: when public money helps steady the ladder, private billing should not act like it built the building alone.

    America gets cast as both venture capitalist and customer—asked to help finance the uncertain part, then sent shopping at the counter once the emergency treatment is ready. The money trail wore cologne, but the receipt still smells like a double charge: first as research backer, then as buyer. If public science helps make a medical breakthrough possible, why does the public receive so little leverage over the price and so much responsibility for paying it?

  • |

    Rod Stewart and the Luxury of Calling It Minor

    ByAmanda Lynn

    Rod Stewart’s Riverbend Music Center performance in Cincinnati was postponed after what was described as an “unforeseen but minor medical procedure,” and the word minor immediately began doing the work of a stadium roadie. The Associated Press later reported that Stewart underwent a coronary stent procedure, needed about four weeks to recover, and canceled the Cleveland performance along with the remaining dates on his “One Last Time” run. Recovery is the correct priority; nobody needs a rock star treating a doctor’s orders like an encore request.

    But “minor” is a fascinating word when it leaves the medical office and enters the fan inbox. For a physician, it may describe a routine procedure. For a person holding a ticket, it can mean rearranging travel, checking a hotel reservation, shifting a work schedule, and trying to understand whether the venue, promoter, ticket seller, or some mysterious digital cousin of all three has the next answer. The procedure may be small in the clinical sentence while becoming enormous in the calendar.

    Riverbend’s event information and promoter communications are left to carry the practical news about affected performances, which is how modern concertgoing turns a human health event into a relay race of notices. One cheerful update says postponed. Another says canceled. Somewhere, a fan is refreshing an account page with the haunted expression of someone who has paid in advance to become a part-time logistics coordinator.

    The target here is not Stewart, his heart, or his need to rest. The target is the soft language and fragmented ticketing system that make a major disruption sound like a gentle adjustment to the evening. Fans understand that health comes before a concert. They also deserve clear instructions about what happens next without having to assemble the answer from venue pages, promoter messages, ticket portals, and the spiritual residue of customer service.

    So let “minor” take its final bow. Medically routine can still be personally expensive, exhausting, and anything but minor to the person with a ticket, a hotel, a work shift, and an inbox full of automated reassurance. The song matters, absolutely. But when the tour stops, the invoice—and the explanation—should not be left waiting outside the venue.

  • |

    Public Grants, Private Tollbooth: Who Pays Twice for Xtandi?

    ByPhil McCracken

    At my invoice desk, the Xtandi money trail arrives wearing a lab coat and leaves in a limousine. The complaint is straightforward: public funding helped support UCLA-linked research, while commercialization and patent control became associated with Astellas and Pfizer. Then patients encountered annual U.S. price claims reaching roughly $160,000 to $180,000. That is a remarkable billing arrangement—taxpayers help finance the road, private interests control the toll gate, and the patient gets charged for driving on it.

    Not every stage of Xtandi’s development can be reduced to one public grant or one private decision, and a list price is not the same as every patient’s bill. But the public-return question remains as stubborn as a bad line item: when public science helps move an essential medicine forward, what does the public receive besides another invoice? Innovation may begin as public service, yet somehow ends as private property with a collections department. Follow the invoice long enough and it reaches the same destination: the patient, standing at the pharmacy counter with the receipt and no lobbyist’s expense account.

  • |

    The Drug-Price Mystery Has a Lobbying Budget

    ByPhil McCracken

    Patients receive a prescription bill written like a ransom note from an accountant, while the pharmaceutical industry’s Washington invoice arrives in plain English. Bloomberg Government reported that PhRMA spent $7.4 million lobbying in the second quarter of 2026, bringing its year-to-date total to $19.6 million. I have seen less money spent renovating an entire Capitol Hill office, although admittedly fewer people were trying to influence the rulebook.

    That spending does not, by itself, prove that lobbying caused any particular drug price or defeated any particular proposal. It does reveal something less mysterious: the trade group representing major pharmaceutical interests has a very clear budget for being present while everyone else debates why medicine costs so much. When an industry spends millions to participate in the policy conversation, “expertise” starts looking a lot like a reserved seat with better coffee.

    The timing is the whole money trail. Washington continued debating Medicare negotiation, most-favored-nation pricing, and other proposals aimed at lowering costs. Those are policy arguments, not settled outcomes, and they deserve scrutiny on their details. But patients are routinely told that drug pricing is too complex for ordinary people to understand, just as the people affected by the bill are asked to wait outside the room while well-funded representatives explain the machinery.

    That is the access economy in its natural habitat: the public gets a maze of rebates, formularies, negotiations, and carefully polished explanations; lobbyists get calendars, meetings, and a professional vocabulary for turning private interests into public homework. The pharmaceutical lobbying total reported by Bloomberg Government is not the entire industry’s spending, and it is not evidence of illegal conduct. It is simply a large, legible number attached to an argument that is often presented as impossibly complicated.

    So Washington keeps searching for the missing answer to drug prices. Meanwhile, the money trail has already found the billing department. Patients get the mystery, lobbyists get the appointment calendar, and taxpayers get another explanation for why reform remains under review.

    Sources

  • |

    The CDC’s Autism Page Is Doing the ‘Just Asking Questions’ Fog Machine

    ByHolden McGroin

    My corkboard has identified a new suspect in the vaccine misinformation loop: the CDC communications department, apparently operating a fog machine with a government email address. The agency’s revised autism page reopens uncertainty around vaccines, while its separate MMR safety page says many carefully performed studies found no link between MMR vaccination and autism. That is not clarity. That is two official webpages standing in the hallway, pointing at each other, while parents are told to bring their own flashlight.

    The contradiction matters because public-health guidance is supposed to reduce confusion, not make ordinary people perform a graduate seminar between school pickup and dinner. The autism page says the claim that vaccines do not cause autism is not evidence-based, according to the CDC’s current language, while also retaining a citation to a hepatitis B study reported by NOTUS as retracted and methodologically problematic. A retracted study should not be treated like a fresh clue in a detective novel unless the detective is selling supplements on a livestream.

    Meanwhile, the CDC’s MMR page presents the more familiar evidence-based position: many carefully performed studies found no link between MMR vaccination and autism. Those pages do not create a productive scientific debate for families. They create a credibility crisis for the institution that is supposed to explain what is known, what is uncertain, and what has been discredited. The algorithm, naturally, sees only engagement potential. Every official wobble becomes premium content for rumor accounts, influencers, and anyone whose business model requires the public to stay permanently alarmed.

    Associated Press coverage reported political responses and Senate scrutiny surrounding the CDC’s revised language. That response is part of the larger problem: scientific communication starts looking like political collateral, edited according to whichever faction is currently demanding a dramatic question mark. The beneficiaries are not the families stuck sorting claims from evidence. They are the panic merchants, who get to convert institutional ambiguity into clicks, subscriptions, and another exhausting group-chat emergency.

    The CDC did not merely fail to clear the smoke. It appears to be revising the fog machine’s instruction manual while insisting everyone remain calm. People deserve public-health agencies that can acknowledge uncertainty without laundering discredited material or contradicting their own guidance. Follow the thread, sure—but check the knot before somebody charges admission to the maze.

  • |

    ChatGPT Wants Your Medical Records, But Not the Responsibility

    ByLee Keybum

    Lee Keybum reads the terms so you do not have to, and OpenAI’s new Health feature comes with a very modern trust bargain: ChatGPT can become familiar with your connected medical records, lab results, prescriptions, Apple Health data, and health conversations, but it still wants to be treated as support rather than medical care. OpenAI announced the U.S. rollout on July 23, describing Health in ChatGPT as a place for personalized guidance and health-related conversations. That is a lot of intimate information to hand to a general-purpose chatbot before it politely reminds you that it is not intended to diagnose or treat anything.

    The contradiction is not hidden; it is laminated into the product. The more information ChatGPT can use, the more naturally it can sound like the friend who knows why every pill is in the cabinet and which lab result made you stare at the ceiling. But OpenAI says the service does not replace qualified medical professionals. In ordinary-person language, the platform wants the context required to sound medically informed while preserving an escape hatch if the conversation wanders into actual medical responsibility.

    OpenAI’s health privacy policy also says connected health data is not used to train its foundation models or target ads by default. That matters, and “by default” matters too. It is not a promise that every possible privacy concern has evaporated into the cloud. It means the company’s stated bargain is narrower: users may authorize sensitive data connections for the feature, while OpenAI says those connections are treated differently from ordinary ChatGPT data for model training and advertising.

    For users, the practical question is not whether the chatbot can produce a soothing paragraph about wellness. It is whether convenience quietly turns the app into the most informed entity in a person’s medical life without giving that entity the accountability people normally expect from medical care. A doctor has credentials, professional rules, and a human being attached to the decision. ChatGPT has a privacy policy, a disclaimer, and a remarkable talent for making a sentence sound settled before the facts are.

    That is the subscription-barnacle version of artificial intelligence: first it asks for your bloodwork, sleep history, medication list, and trust; then, if the answer is wrong, it becomes a very confident autocomplete with no medical license. OpenAI may call Health a support tool, but the user experience is built to feel personal and informed. The company wants the data that makes the system sound like a doctor while keeping the responsibility label safely out of frame.

End of content

End of content